Affinnova, Inc.

Affinnova, Inc. Raises $4.5 Million in C Round from Sherbrooke Capital and Flagship Ventures

Affinnova, Inc. Raises $4.5 Million in C Round from Sherbrooke Capital and Flagship Ventures

August 17, 2004

Capital investment to accelerate market penetration, extend technology leadership and build operational capabilities to support growing industry adoption of IDEA(TM) Technology

Selventa

Genstruct and Berlex Biosciences Collaborate on Breast Carcinoma Research

Genstruct and Berlex Biosciences Collaborate on Breast Carcinoma Research

September 15, 2004

CAMBRIDGE, Mass., September 15, 2004 - Genstruct Inc., a knowledge-driven discovery company, announced today that it has entered into an agreement with Berlex, Inc., a U.S. affiliate of Schering AG, Germany (NYSE: SHR, FSE: SCH), to characterize the regulatory mechanisms for breast cancer. The goal is to uncover the causal mechanisms for the initiation of breast cancer to better understand the genes, proteins and metabolites that play crucial roles in the development of this disease.

Adnexus Therapeutics

Compound Therapeutics and Abbott Laboratories Enter into Technology License Agreement for Drug Discovery

Compound Therapeutics and Abbott Laboratories Enter into Technology License Agreement for Drug Discovery

September 29, 2004

WALTHAM, Mass., Sept. 29 /PRNewswire/ -- Compound Therapeutics, a Massachusetts-based biotechnology company, announced today that they have entered into a license agreement with Abbott Laboratories granting Abbott non- exclusive rights to use Compound Therapeutics' PROfusion(TM) technology and certain antibody libraries. PROfusion is an in vitro display technology for the selection and rapid optimization of high-affinity antibodies and other binding proteins.

Black Duck Software, Inc.

Black Duck Names Noted Open Source Attorney Lawrence Rosen as Senior Advisor

Black Duck Names Noted Open Source Attorney Lawrence Rosen as Senior Advisor

October 4, 2004

Waltham, Mass., October 4, 2004 -- Black Duck Software, the leading provider of software compliance management solutions for governing software assets, today announced that Lawrence Rosen has joined the company as a senior advisor. Rosen, a noted attorney and computer specialist, is the author of Open Source Licensing: Software Freedom and Intellectual Property Law, which was published earlier this year.

Selventa

Genstruct Enters Into a Multi-Year Collaboration

Genstruct Enters Into a Multi-Year Collaboration

November 8, 2004

CAMBRIDGE, Mass., Nov. 8 /PRNewswire/ -- Genstruct Inc., a knowledge-driven discovery company, announced today that it has signed an agreement with Pfizer to collaborate on a variety of research projects to help better understand complex diseases. This deal is part of a continuing, multiyear relationship Genstruct has developed with Pfizer. Terms of the partnership are not being disclosed.

e-Dialog, Inc.

e-Dialog Strengthens Leadership Team and Increases Client Resources to Meet Growing Demand for Precision E-Mail Marketing

e-Dialog Strengthens Leadership Team and Increases Client Resources to Meet Growing Demand for Precision E-Mail Marketing

November 16, 2004

Company Appoints Three New Vice Presidents to Analytics, Sales, Marketing and Professional Services; Significantly Boosts Client Service Teams

BG Medicine, Inc.

FDA and Industry to Collaborate on Better Ways to Predict Liver Toxicity in Human Drug Trials

FDA and Industry to Collaborate on Better Ways to Predict Liver Toxicity in Human Drug Trials

November 2, 2005

Part of FDA’s Critical Path Initiative to Modernizing Drug Development

The U.S. Food and Drug Administration and BG Medicine, a Massachusetts-based biotechnology research company, have agreed to collaborate on a project designed to overcome one of the obstacles to efficient development of safe drugs.

TripAdvisor LLC

Flagship Portfolio Companies Highlighted in Boston Globe Articles

Flagship Portfolio Companies Highlighted in Boston Globe Articles

January 18, 2005

Three of Flagship's portfolio companies that specialize in Internet search technology were highlighted prominently in two articles in The Boston Globe's Sunday Business section on Monday, January 17, 2005. All three represent investments made by Flagship when other venture capital firms were retrenching and cautious about supporting search technologies. We continued to believe that there was money to be made in this area, and today all three companies (EasyAsk, Eliyon Technologies, and TripAdvisor) are in revenue phases, near or well beyond break-even.

Adnexus Therapeutics

Compound Therapeutics, Inc. Raises $15.5 Million to Advance Product Pipeline Into Clinic

Compound Therapeutics, Inc. Raises $15.5 Million to Advance Product Pipeline Into Clinic

January 18, 2005

WALTHAM, Mass., Jan. 18 /PRNewswire/ -- Compound Therapeutics, Inc., a privately held biotechnology company, today announced that it has raised an additional $15.5 million in an expansion of its Series A financing. These funds will be used to advance Compound's lead oncology product candidate into the clinic and to build the company's pipeline by moving additional programs into preclinical development. Compound is developing the next generation of biotherapeutics with its AdNectin and AdZyme technologies.

Flagship Ventures Has Moved Effective January 31, 2005

Flagship Ventures Has Moved Effective January 31, 2005

January 31, 2005


is pleased to announce

our new address effective January 31, 2005: